N Engl J Med JANUARY 08, 2009

Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes (VADT)

William Duckworth, Carlos Abraira, Thomas Moritz, Domenic Reda, Nicholas Emanuele, Peter D. Reaven et al.

Bottom Line

In older military veterans with long-standing, poorly controlled type 2 diabetes, intensive glucose control did not significantly reduce major cardiovascular events or all-cause mortality compared to standard therapy, but did increase the risk of severe hypoglycemia.

Key Findings

1. Over a median follow-up of 5.6 years, median glycated hemoglobin (HbA1c) levels achieved were 6.9% in the intensive-therapy group versus 8.4% in the standard-therapy group.

2. The primary composite cardiovascular outcome occurred in 235 patients in the intensive group and 264 in the standard group (Hazard Ratio [HR] 0.88; 95% CI, 0.74 to 1.05; P=0.14), demonstrating no statistically significant difference.

3. There was no significant difference observed for all-cause mortality between the intensive and standard control groups (HR 1.07; 95% CI, 0.81 to 1.42; P=0.62).

4. No significant differences were observed between the two groups for overall microvascular complications, with the exception of a significant reduction in the progression of albuminuria in the intensive-therapy arm (P=0.01).

5. Adverse events, predominantly severe hypoglycemia, were significantly higher in the intensive-therapy group (24.1%) compared to the standard-therapy group (17.6%).

Study Design

Design

RCT

Open-Label

Sample

1,791

Patients

Duration

5.6 yr

Median

Setting

Multicenter, US

Population Military veterans (mean age 60.4 years) with suboptimally controlled type 2 diabetes and a mean disease duration of 11.5 years.

Intervention Intensive glucose control aiming for an absolute reduction of 1.5 percentage points in HbA1c compared to standard therapy, targeting near-normal levels.

Comparator Standard glucose control.

Outcome Time to first major cardiovascular event (composite of myocardial infarction, stroke, cardiovascular death, congestive heart failure, vascular surgery, inoperable coronary disease, or amputation for ischemic gangrene).

Study Limitations

• The median follow-up of 5.6 years may have been too short to detect a long-term divergence in macrovascular outcomes, especially considering the prolonged timeline of atherosclerotic progression.

• The study cohort was overwhelmingly older male military veterans with long-standing diabetes (mean duration 11.5 years) and a high baseline prevalence of cardiovascular disease (40%), which limits the generalizability of the findings to younger, newly diagnosed, or female patients.

• High rates of severe hypoglycemia in the intensive arm could have precipitated adverse cardiovascular events, potentially masking or counteracting any ischemic benefits of tight glycemic control.

• The trial may have been underpowered to detect modest but clinically meaningful differences in specific individual components of the broad composite primary outcome.

Clinical Significance

The VADT trial provided critical evidence that in older patients with long-standing type 2 diabetes and established cardiovascular risk factors, pursuing near-normal glycemic targets (HbA1c of 6.9%) does not reduce major macrovascular events over a 5.6-year period. Conversely, such intensive control exposes these vulnerable patients to a substantially increased risk of severe hypoglycemia. Alongside similar contemporaneous trials, VADT forced a profound paradigm shift in clinical practice from a universal 'treat-to-target' approach to individualized HbA1c goals that weigh a patient's age, comorbidities, disease duration, and hypoglycemia risk.

Historical Context

Prior to 2008, diabetes management was heavily influenced by the DCCT (type 1 diabetes) and UKPDS (newly diagnosed type 2 diabetes) trials, which established that intensive glycemic control prevents microvascular complications and hinted at long-term 'legacy' macrovascular benefits. This engendered widespread guidelines advocating for tight HbA1c targets (<7.0%) for nearly all patients. Published in early 2009, the VADT trial reported its findings concurrently with the landmark ACCORD and ADVANCE trials. Together, this triad of robust trials challenged prevailing medical dogma, proving that aggressively lowering glucose in older populations with established, long-standing type 2 diabetes yielded no short-to-medium-term cardiovascular benefit and increased the risk of severe hypoglycemia (and mortality, in the case of ACCORD). These results revolutionized modern guidelines, ushering in the current era of personalized, patient-centered glycemic targets.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

Why might intensive glucose control fail to prevent macrovascular complications like myocardial infarction in long-standing type 2 diabetes, even though it effectively reduces microvascular complications like retinopathy?

Key Response

Microvascular complications are directly driven by endothelial glucose toxicity and intracellular sorbitol accumulation. In contrast, macrovascular complications in long-standing diabetes are driven by advanced, irreversible atherosclerotic plaques. By the time diabetes has been present for 10 to 15 years, as in the VADT cohort, lowering glucose does not reverse established atheromas, highlighting the difference between microvascular and macrovascular pathophysiology.

Resident

A 72-year-old veteran with a 15-year history of type 2 diabetes, prior MI, and an HbA1c of 8.8 percent presents to the clinic. How do the findings of the VADT study influence your decision on whether to aggressively titrate their insulin to achieve an HbA1c of less than 7.0 percent?

Key Response

The VADT study demonstrated that in older patients with long-standing diabetes, intensive control does not reduce cardiovascular events but significantly increases the risk of severe hypoglycemia. Therefore, clinical management should focus on relaxing the HbA1c target to 7.5 to 8.0 percent for this patient to prioritize safety and quality of life over aggressive numerical control.

Fellow

Post-hoc analyses of the VADT study suggested a relationship between diabetes duration and the cardiovascular response to intensive glycemic control. How does the concept of disease duration create a window of opportunity for cardiovascular risk reduction in endocrinology?

Key Response

Subgroup analyses revealed that patients with a diabetes duration of less than 12 to 15 years prior to intensive therapy initiation experienced some cardiovascular benefit, whereas those with longer disease duration experienced no benefit or even harm. This suggests a metabolic window wherein early intensive glycemic control can modify macrovascular trajectory, whereas late intervention is futile against calcified, complex atherosclerotic disease.

Attending

When teaching trainees on the wards, how do you synthesize the seemingly contradictory findings of the UKPDS legacy effect, which showed cardiovascular benefit from early intensive control, with the VADT findings of no cardiovascular benefit from late intensive control?

Key Response

I use this comparison to teach the critical importance of early intervention. UKPDS studied newly diagnosed patients, showing that early glycemic control prevents the formation of atherosclerotic substrate, creating a long-term legacy effect. VADT studied patients with an average 11.5-year history of poorly controlled disease, teaching us that once the atherosclerotic burden is established, aggressive glucose lowering cannot undo the structural vascular damage and introduces life-threatening hypoglycemia.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

The VADT utilized a treat-to-target algorithmic design requiring multiple, varying medications to achieve glycemic goals in the intensive arm. What are the major methodological threats to internal validity when isolating the independent effect of glucose lowering in this specific trial design?

Key Response

A treat-to-target design introduces significant confounding by medication class. In VADT, the intensive arm required much higher doses of insulin and rosiglitazone. Since rosiglitazone has debated cardiovascular risks and hyperinsulinemia may promote weight gain and atherogenesis, it is statistically impossible to fully decouple the effect of the lower HbA1c from the potentially cardiotoxic off-target effects of the aggressive pharmacotherapy used to achieve it.

Journal Editor

As a peer reviewer analyzing the VADT manuscript, how would you critique the impact of the massive increase in background statin and anti-hypertensive use during the trial period on the statistical power of the primary cardiovascular composite outcome?

Key Response

A tough reviewer would flag that the background standard of care improved drastically during the study, with statin use rising to over 85 percent and blood pressure control significantly tightening. This dramatically lowered the baseline cardiovascular event rate across both arms compared to initial power calculations, raising the possibility of a Type II error where the trial was ultimately underpowered to detect a small but potentially real difference in macrovascular outcomes.

Guideline Committee

The ADA guidelines currently recommend relaxing HbA1c targets for older adults with multiple comorbidities. How does the VADT study provide Level A evidence for these recommendations, and should future guidelines explicitly mandate de-intensification algorithms rather than just permissive targets?

Key Response

VADT provides definitive Level A evidence that intensive control in older adults with long-standing diabetes yields no mortality or cardiovascular benefit while tripling the rate of severe hypoglycemia. While current ADA guidelines suggest less stringent targets like less than 8.0 percent for complex patients, incorporating structured de-intensification protocols into the guidelines would systematically prevent the clinical inertia that keeps older patients on dangerous insulin or sulfonylurea regimens long after the window for macrovascular benefit has closed.

Clinical Landscape

Noteworthy Related Trials

1998

UKPDS 33

n = 3,867 · Lancet

Tested

Intensive blood-glucose control with sulfonylureas or insulin

Population

Newly diagnosed T2DM patients

Comparator

Conventional treatment (dietary restriction)

Endpoint

Any diabetes-related endpoint, diabetes-related death, and all-cause mortality

Key result: Intensive control significantly decreased the risk of microvascular complications but not macrovascular disease initially, though a legacy effect was seen years later.

2008

ACCORD Trial

n = 10,251 · NEJM

Tested

Intensive glucose control (target HbA1c < 6.0%)

Population

T2DM patients with high CV risk

Comparator

Standard glucose control (target HbA1c 7.0-7.9%)

Endpoint

Nonfatal MI, nonfatal stroke, or CV death (3-point MACE)

Key result: Intensive therapy did not significantly reduce major CV events but was associated with increased all-cause mortality, leading to early termination of the intensive arm.

2008

ADVANCE Trial

n = 11,140 · NEJM

Tested

Intensive glucose control (target HbA1c <= 6.5% using gliclazide MR)

Population

T2DM patients with high cardiovascular risk

Comparator

Standard glucose control

Endpoint

Composite of major macrovascular or microvascular events

Key result: Intensive control reduced the incidence of combined major macro- and microvascular events, primarily driven by a reduction in nephropathy, but had no significant effect on major macrovascular events.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis